Primary refractory acute myeloid leukaemia - in search of better definitions and therapies

British Journal of Haematology

Volumn 155, Issue 4, 2011, Pages 413-419

  Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukaemia; Chemoresistant; Chemosensitive; Primary refractory

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054983096     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08869.x     Document Type: Review

References (40)

1. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. & Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 3481-3485.
2. Baer, M.R., George, S.L., Sanford, B.L., Mrozek, K., Kolitz, J.E., Moore, J.O., Stone, R.M., Powell, B.L., Caligiuri, M.A., Bloomfield, C.D. & Larson, R.A. (2011) Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60years and older: Cancer and Leukemia Group B Study 9720. Leukemia, 25, 800-807.
3. Biggs, J.C., Horowitz, M.M., Gale, R.P., Ash, R.C., Atkinson, K., Helbig, W., Jacobsen, N., Phillips, G.L., Rimm, A.A., Ringden, O. et al (1992) Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood, 80, 1090-1093.
4. Bishop, J.F., Matthews, J.P., Young, G.A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M.M., Fox, R., Cobcroft, R., Herrmann, R., Van Der Weyden, M., Lowenthal, R.M., Page, F., Garson, O.M. & Juneja, S. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 1710-1717.
5. Burnett, A.K., Hills, R.K., Milligan, D.W., Goldstone, A.H., Prentice, A.G., McMullin, M.F., Duncombe, A., Gibson, B. & Wheatley, K. (2009) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology, 28, 586-595.
6. Campana, D. (2010) Minimal residual disease in acute lymphoblastic leukemia. Hematology/The Education Program of the American Society of Hematology, 2010, 7-12.
7. Chen, Y., Cortes, J., Estrov, Z., Faderl, S., Qiao, W., Abruzzo, L., Garcia-Manero, G., Pierce, S., Huang, X., Kebriaei, P., Kadia, T., De Lima, M., Kantarjian, H. & Ravandi, F. (2011) Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem cell transplantation. Journal of Clinical Oncology, 29, 2507-2513.
8. Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R., Keating, M.J., Sawitsky, A., Stass, S., Weinstein, H. & Woods, W.G. (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology, 8, 813-819.
9. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642-4649.
10. Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B.A., Jansen, J.H., van der Velden, V.H., Ommen, H., Preudhomme, C., Saglio, G. & Grimwade, D. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Journal of Clinical Oncology, 27, 5195-5201.
11. Craddock, C., Labopin, M., Pillai, S., Finke, J., Bunjes, D., Greinix, H., Ehninger, G., Steckel, N.K., Zander, A.R., Schwerdtfeger, R., Buchholz, S., Kolb, H.J., Volin, L., Fauser, A., Polge, E., Schmid, C., Mohty, M. & Rocha, V. (2011) Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia, 25, 808-813.
12. Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Lowenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453-474.
13. Duval, M., Klein, J.P., He, W., Cahn, J.Y., Cairo, M., Camitta, B.M., Kamble, R., Copelan, E., de Lima, M., Gupta, V., Keating, A., Lazarus, H.M., Litzow, M.R., Marks, D.I., Maziarz, R.T., Rizzieri, D.A., Schiller, G., Schultz, K.R., Tallman, M.S. & Weisdorf, D. (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. Journal of Clinical Oncology, 28, 3730-3738.
14. Estey, E.H., Thall, P.F., Wang, X., Verstovsek, S., Cortes, J. & Kantarjian, H.M. (2003) Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood, 102, 3097-3099.
15. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A.F., Gore, S., Seymour, J.F., Dombret, H., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C.L. & Silverman, L.R. (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology, 28, 562-569.
16. Fernandez, H.F., Sun, Z., Yao, X., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M. & Tallman, M.S. (2009) Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361, 1249-1259.
17. Freireich, E.J., Gehan, E.A., Sulman, D., Boggs, D.R. & Frei, E. 3rd (1961) The effect of chemotherapy on acute leukemia in the human. Journal of Chronic Diseases, 14, 593-608.
18. Fung, H.C., Stein, A., Slovak, M., O'Donnell, M.R., Snyder, D.S., Cohen, S., Smith, D., Krishnan, A., Spielberger, R., Bhatia, R., Bhatia, S., Falk, P., Molina, A., Nademanee, A., Parker, P., Rodriguez, R., Rosenthal, J., Sweetman, R., Kogut, N., Sahebi, F., Popplewell, L., Vora, N., Somlo, G., Margolin, K., Chow, W., Smith, E. & Forman, S.J. (2003) A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biology of Blood and Marrow Transplantation, 9, 766-771.
19. Grimwade, D., Jovanovic, J.V., Hills, R.K., Nugent, E.A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, R.E., Solomon, E., Lo-Coco, F., Wheatley, K. & Burnett, A.K. (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology, 27, 3650-3658.
20. Grimwade, D., Vyas, P. & Freeman, S. (2010) Assessment of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 22, 656-663.
21. Hokland, P. & Ommen, H.B. (2011) Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood, 117, 2577-2584.
22. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J. & Estey, E. (2006) Results of intensive chemotherapy in 998 patients age 65years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer, 106, 1090-1098.
23. Kern, W. & Estey, E.H. (2006) High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer, 107, 116-124.
24. Kern, W., Haferlach, T., Schoch, C., Loffler, H., Gassmann, W., Heinecke, A., Sauerland, M.C., Berdel, W., Buchner, T. & Hiddemann, W. (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood, 101, 64-70.
25. Kern, W., Bacher, U., Haferlach, C., Schnittger, S. & Haferlach, T. (2010) The role of multiparameter flow cytometry for disease monitoring in AML. Best Practice & Research. Clinical Haematology, 23, 379-390.
26. Kronke, J., Schlenk, R.F., Jensen, K.O., Tschurtz, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., Spath, D., Lubbert, M., Wattad, M., Kindler, T., Salih, H.R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H.G., Krauter, J., Ganser, A., Gohring, G., Schlegelberger, B., Dohner, H. & Dohner, K. (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of Clinical Oncology, 29, 2709-2716.
27. Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., McConnell, T.S., Head, D.R., Weick, J., Grever, M.R., Appelbaum, F.R. & Willman, C.L. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94, 1086-1099.
28. Lowenberg, B., Ossenkoppele, G.J., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B.J., Vellenga, E., van Marwijk Kooy, M., Verdonck, L.F., Beck, J., Dohner, H., Gratwohl, A., Pabst, T. & Verhoef, G. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine, 361, 1235-1248.
29. Lowenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B.J., Gratwohl, A., de Greef, G.E., Verdonck, L.F., Schaafsma, M.R., Gregor, M., Theobald, M., Schanz, U., Maertens, J. & Ossenkoppele, G.J. (2011) Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364, 1027-1036.
30. Marcucci, G., Mrozek, K., Ruppert, A.S., Archer, K.J., Pettenati, M.J., Heerema, N.A., Carroll, A.J., Koduru, P.R., Kolitz, J.E., Sterling, L.J., Edwards, C.G., Anastasi, J., Larson, R.A. & Bloomfield, C.D. (2004) Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. Journal of Clinical Oncology, 22, 2410-2418.
31. Plunkett, W., Liliemark, J.O., Estey, E. & Keating, M.J. (1987) Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Seminars in Oncology, 14, 159-166.
32. Ravandi, F., Cortes, J.E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M.Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S.R., Brandt, M., Byrd, A., Bekele, B.N., Pratz, K., Luthra, R., Levis, M., Andreeff, M. & Kantarjian, H.M. (2010a) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology, 28, 1856-1862.
33. Ravandi, F., Cortes, J., Faderl, S., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Santos, F.P., Shan, J., Brandt, M., de Lima, M., Pierce, S. & Kantarjian, H. (2010b) Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood, 116, 5818-5823; quiz 6153.
34. Rowe, J.M., Kim, H.T., Cassileth, P.A., Lazarus, H.M., Litzow, M.R., Wiernik, P.H. & Tallman, M.S. (2010) Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer, 116, 5012-5021.
35. Schmid, C., Schleuning, M., Schwerdtfeger, R., Hertenstein, B., Mischak-Weissinger, E., Bunjes, D., Harsdorf, S.V., Scheid, C., Holtick, U., Greinix, H., Keil, F., Schneider, B., Sandherr, M., Bug, G., Tischer, J., Ledderose, G., Hallek, M., Hiddemann, W. & Kolb, H.J. (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood, 108, 1092-1099.
36. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood, 114, 2220-2231.
37. Smith, M.L., Hills, R.K. & Grimwade, D. (2011) Independent prognostic variables in acute myeloid leukaemia. Blood Reviews, 25, 39-51.
38. Stone, R.M. (2010) New agents in post-remission therapy. Best Practice & Research. Clinical Haematology, 23, 475-479.
39. Walter, R.B., Kantarjian, H.M., Huang, X., Pierce, S.A., Sun, Z., Gundacker, H.M., Ravandi, F., Faderl, S.H., Tallman, M.S., Appelbaum, F.R. & Estey, E.H. (2010) Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. Journal of Clinical Oncology, 28, 1766-1771.
40. Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M., Harrison, C.J., Rees, J.K., Stevens, R.F. & Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. British Journal of Haematology, 107, 69-79.